Generated: April 27, 2017
|Title:||Extended release opioid abuse deterrent compositions and methods of making same|
|Abstract:||This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.|
|Inventor(s):||Kumar; Vijai (Morris Plains, NJ), Dixon; David (Woodside, NY), Tewari; Divya (Suffern, NY), Wadgaonkar; Dilip B. (Suffern, NY)|
|Assignee:||Acura Pharmaceuticals, Inc. (Palantine, IL)|
|Filing Date:||Mar 30, 2009|
|Claims:||1. An extended release abuse deterrent dosage form comprising: a. a core matrix comprising a blended mixture of: (a) PEO having a molecular weight of from about 300,000 to about 5,000,000; (b) magnesium stearate; and (c) oxycodone or a pharmaceutically acceptable salt thereof; wherein the matrix is heated to melt at least a portion of the PEO included in the matrix; and b. PEG applied onto the core matrix; wherein the dosage form provides extended release of the drug.|
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.